Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout
→ Cell therapy R&D is hot, and Charles River Labs $CRL knows it. The CRO is paying $380 million to acquire HemaCare, a company that provides material and services for companies developing off-the-shelf and personalized cell therapies. Charles River says it’s developing a turnkey service for cell therapy developers and manufacturers.
“Cell and gene therapies are important new modalities, with an estimated 10 to 20 new product approvals per year within five years,” notes Charles River CEO James Foster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.